In breast cancer, differential gene profiling revealed that the expression of CD9 was higher in metastatic cancer cells when compared with that of the corresponding primary tumor cells, despite that in the majority of cases, expression of motility-related protein-1 (MRP-1/CD9) was downregulated in metastatic carcinoma cells (24). This evidence concerns the gene CD9 and breast carcinoma.